Literature DB >> 29558366

Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression.

Yawara Kawano1,2, Oksana Zavidij1, Jihye Park1, Michele Moschetta1, Katsutoshi Kokubun1, Tarek H Mouhieddine1, Salomon Manier1, Yuji Mishima1, Naoka Murakami3, Mark Bustoros1, Romanos Sklavenitis Pistofidis1, Mairead Reidy1, Yu J Shen1, Mahshid Rahmat1, Pavlo Lukyanchykov3, Esilida Sula Karreci3, Shokichi Tsukamoto1, Jiantao Shi4, Satoshi Takagi1, Daisy Huynh1, Antonio Sacco1,5, Yu-Tzu Tai1, Marta Chesi6, P Leif Bergsagel6, Aldo M Roccaro1,5, Jamil Azzi3, Irene M Ghobrial1.   

Abstract

Despite significant advances in the treatment of multiple myeloma (MM), most patients succumb to disease progression. One of the major immunosuppressive mechanisms that is believed to play a role in myeloma progression is the expansion of regulatory T cells (Tregs). In this study, we demonstrate that myeloma cells drive Treg expansion and activation by secreting type 1 interferon (IFN). Blocking IFN α and β receptor 1 (IFNAR1) on Tregs significantly decreases both myeloma-associated Treg immunosuppressive function and myeloma progression. Using syngeneic transplantable murine myeloma models and bone marrow (BM) aspirates of MM patients, we found that Tregs were expanded and activated in the BM microenvironment at early stages of myeloma development. Selective depletion of Tregs led to a complete remission and prolonged survival in mice injected with myeloma cells. Further analysis of the interaction between myeloma cells and Tregs using gene sequencing and enrichment analysis uncovered a feedback loop, wherein myeloma-cell-secreted type 1 IFN induced proliferation and expansion of Tregs. By using IFNAR1-blocking antibody treatment and IFNAR1-knockout Tregs, we demonstrated a significant decrease in myeloma-associated Treg proliferation, which was associated with longer survival of myeloma-injected mice. Our results thus suggest that blocking type 1 IFN signaling represents a potential strategy to target immunosuppressive Treg function in MM.

Entities:  

Keywords:  Hematology; Immunology; T cells

Mesh:

Substances:

Year:  2018        PMID: 29558366      PMCID: PMC5983341          DOI: 10.1172/JCI88169

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  61 in total

1.  Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma.

Authors:  Katjana Klages; Christian T Mayer; Katharina Lahl; Christoph Loddenkemper; Michele W L Teng; Shin Foong Ngiow; Mark J Smyth; Alf Hamann; Jochen Huehn; Tim Sparwasser
Journal:  Cancer Res       Date:  2010-10-05       Impact factor: 12.701

2.  Dysfunctional T regulatory cells in multiple myeloma.

Authors:  Rao H Prabhala; Paola Neri; Jooeun E Bae; Pierfrancesco Tassone; Masood A Shammas; Charles K Allam; John F Daley; Dharminder Chauhan; Elizabeth Blanchard; Hemant S Thatte; Kenneth C Anderson; Nikhil C Munshi
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

Review 3.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

4.  LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites.

Authors:  Chiara Camisaschi; Chiara Casati; Francesca Rini; Michela Perego; Annamaria De Filippo; Frédéric Triebel; Giorgio Parmiani; Filiberto Belli; Licia Rivoltini; Chiara Castelli
Journal:  J Immunol       Date:  2010-04-26       Impact factor: 5.422

5.  Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy.

Authors:  Marta Chesi; Geoffrey M Matthews; Victoria M Garbitt; Stephen E Palmer; Jake Shortt; Marcus Lefebure; A Keith Stewart; Ricky W Johnstone; P Leif Bergsagel
Journal:  Blood       Date:  2012-03-26       Impact factor: 22.113

6.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

7.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

8.  Rig-I-/- mice develop colitis associated with downregulation of G alpha i2.

Authors:  Yi Wang; Hong-Xin Zhang; Yue-Ping Sun; Zi-Xing Liu; Xue-Song Liu; Long Wang; Shun-Yuan Lu; Hui Kong; Qiao-Ling Liu; Xi-Hua Li; Zhen-Yu Lu; Sai-Juan Chen; Zhu Chen; Shi-San Bao; Wei Dai; Zhu-Gang Wang
Journal:  Cell Res       Date:  2007-10       Impact factor: 25.617

9.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome.

Authors:  Bo Li; Colin N Dewey
Journal:  BMC Bioinformatics       Date:  2011-08-04       Impact factor: 3.307

10.  Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease.

Authors:  Katharina Lahl; Christoph Loddenkemper; Cathy Drouin; Jennifer Freyer; Jon Arnason; Gérard Eberl; Alf Hamann; Hermann Wagner; Jochen Huehn; Tim Sparwasser
Journal:  J Exp Med       Date:  2007-01-02       Impact factor: 14.307

View more
  35 in total

Review 1.  Type I interferon signaling, regulation and gene stimulation in chronic virus infection.

Authors:  Sabelo Lukhele; Giselle M Boukhaled; David G Brooks
Journal:  Semin Immunol       Date:  2019-05-30       Impact factor: 11.130

2.  Down-Regulation of ID2-AS1 Alleviates the Neuronal Injury Induced by 1-Methy1-4-Phenylpyridinium in Human Neuroblastoma Cell Line SH-SY5Y Cells Through Regulating miR-199a-5p/IFNAR1/JAK2/STAT1 Axis.

Authors:  Furong Xu; Hui Wang; Ju Tian; Haiyan Xu
Journal:  Neurochem Res       Date:  2021-05-29       Impact factor: 3.996

3.  Tumor Burden Limits Bispecific Antibody Efficacy through T-cell Exhaustion Averted by Concurrent Cytotoxic Therapy.

Authors:  Erin W Meermeier; Seth J Welsh; Meaghen E Sharik; Megan T Du; Victoria M Garbitt; Daniel L Riggs; Chang-Xin Shi; Caleb K Stein; Marco Bergsagel; Bryant Chau; Matthew L Wheeler; Natalie Bezman; Feng Wang; Pavel Strop; P Leif Bergsagel; Marta Chesi
Journal:  Cancer Discov       Date:  2021-05-05       Impact factor: 39.397

4.  Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model.

Authors:  Camille Guillerey; Kyohei Nakamura; Andrea C Pichler; Deborah Barkauskas; Sophie Krumeich; Kimberley Stannard; Kim Miles; Heidi Harjunpää; Yuan Yu; Mika Casey; Alina I Doban; Mircea Lazar; Gunter Hartel; David Smith; Slavica Vuckovic; Michele Wl Teng; P Leif Bergsagel; Marta Chesi; Geoffrey R Hill; Ludovic Martinet; Mark J Smyth
Journal:  JCI Insight       Date:  2019-06-13

5.  Autologous graft versus myeloma: it's not a myth.

Authors:  Shuai Dong; Irene M Ghobrial
Journal:  J Clin Invest       Date:  2018-11-19       Impact factor: 14.808

6.  The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models.

Authors:  Shih-Feng Cho; Liang Lin; Lijie Xing; Yuyin Li; Kenneth Wen; Tengteng Yu; Phillip A Hsieh; Nikhil Munshi; Joachim Wahl; Katja Matthes; Matthias Friedrich; Tara Arvedson; Kenneth C Anderson; Yu-Tzu Tai
Journal:  Blood Adv       Date:  2020-09-08

Review 7.  Dynamic responses of the haematopoietic stem cell niche to diverse stresses.

Authors:  Antoniana Batsivari; Myriam Luydmila Rachelle Haltalli; Diana Passaro; Constandina Pospori; Cristina Lo Celso; Dominique Bonnet
Journal:  Nat Cell Biol       Date:  2020-01-06       Impact factor: 28.824

8.  Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma.

Authors:  Oksana Zavidij; Nicholas J Haradhvala; Tarek H Mouhieddine; Romanos Sklavenitis-Pistofidis; Songjie Cai; Mairead Reidy; Mahshid Rahmat; Abdallah Flaifel; Benjamin Ferland; Nang K Su; Michael P Agius; Jihye Park; Salomon Manier; Mark Bustoros; Daisy Huynh; Marzia Capelletti; Brianna Berrios; Chia-Jen Liu; Meng Xiao He; Esteban Braggio; Rafael Fonseca; Yosef E Maruvka; Jennifer L Guerriero; Melissa Goldman; Eliezer M Van Allen; Steven A McCarroll; Jamil Azzi; Gad Getz; Irene M Ghobrial
Journal:  Nat Cancer       Date:  2020-04-27

Review 9.  Opposing Roles of Type I Interferons in Cancer Immunity.

Authors:  Giselle M Boukhaled; Shane Harding; David G Brooks
Journal:  Annu Rev Pathol       Date:  2020-12-02       Impact factor: 23.472

10.  Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy.

Authors:  Erin W Meermeier; Seth J Welsh; Meaghen E Sharik; Megan T Du; Victoria M Garbitt; Daniel L Riggs; Chang-Xin Shi; Caleb K Stein; Marco Bergsagel; Bryant Chau; Matthew L Wheeler; Natalie Bezman; Feng Wang; Pavel Strop; P Leif Bergsagel; Marta Chesi
Journal:  Blood Cancer Discov       Date:  2021-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.